Do anti-angiogenic therapies prevent brain metastases in advanced renal cell carcinoma?
Vanhuyse, Marie
Do anti-angiogenic therapies prevent brain metastases in advanced renal cell carcinoma? [electronic resource] - Bulletin du cancer Dec 2012 - 100-6 p. digital
Publication Type: Evaluation Study; Journal Article
1769-6917
10.1684/bdc.2012.1672 doi
Adult
Aged
Aged, 80 and over
Alkaline Phosphatase--blood
Angiogenesis Inhibitors--therapeutic use
Antibodies, Monoclonal, Humanized--therapeutic use
Benzenesulfonates--therapeutic use
Bevacizumab
Brain Neoplasms--blood
Cancer Care Facilities
Carcinoma, Renal Cell--blood
Everolimus
Female
France
Humans
Indoles--therapeutic use
Kidney Neoplasms--blood
Male
Middle Aged
Niacinamide--analogs & derivatives
Phenylurea Compounds
Proportional Hazards Models
Pyridines--therapeutic use
Pyrroles--therapeutic use
Retrospective Studies
Risk Factors
Sirolimus--analogs & derivatives
Sorafenib
Sunitinib
Treatment Outcome
Do anti-angiogenic therapies prevent brain metastases in advanced renal cell carcinoma? [electronic resource] - Bulletin du cancer Dec 2012 - 100-6 p. digital
Publication Type: Evaluation Study; Journal Article
1769-6917
10.1684/bdc.2012.1672 doi
Adult
Aged
Aged, 80 and over
Alkaline Phosphatase--blood
Angiogenesis Inhibitors--therapeutic use
Antibodies, Monoclonal, Humanized--therapeutic use
Benzenesulfonates--therapeutic use
Bevacizumab
Brain Neoplasms--blood
Cancer Care Facilities
Carcinoma, Renal Cell--blood
Everolimus
Female
France
Humans
Indoles--therapeutic use
Kidney Neoplasms--blood
Male
Middle Aged
Niacinamide--analogs & derivatives
Phenylurea Compounds
Proportional Hazards Models
Pyridines--therapeutic use
Pyrroles--therapeutic use
Retrospective Studies
Risk Factors
Sirolimus--analogs & derivatives
Sorafenib
Sunitinib
Treatment Outcome